Table 1.
The baseline characteristics of 260 patients with stage IIB cervical cancer.
| Characteristics | Totality, n (%) | Median (range) |
|---|---|---|
| Age at diagnosis | 260 (100.0%) | 51 (28–74) years |
| Menopause | ||
| Yes | 137 (52.7%) | |
| No | 123 (47.3%) | |
| Age at menopause | 133 (51.2%)a | 49 (24–57) years |
| Pathology | ||
| PDSCC | 8 (3.1%) | |
| MDSCC | 231 (88.8%) | |
| WDSCC | 6 (2.3%) | |
| Adenocarcinoma | 11 (4.2%) | |
| Adenosquamous carcinoma | 3 (1.2%) | |
| Indefinite | 1 (0.4%) | |
| Tumor size | ||
| <4 cm | 78 (30.0%) | |
| ≥4 cm | 182 (70.0%) | |
| Lymphatic metastasis | ||
| Yes | 61 (23.5%) | |
| No | 196 (75.4%) | |
| Not evaluated | 3 (1.2%) | |
| WBC | 260 (100.0%) | 6.45 (2.17–18.61) (×109/L) |
| Neutrophil | 260 (100.0%) | 4.07 (0.96–16.57) (×109/L) |
| Lymphocyte | 260 (100.0%) | 1.60 (0.55–3.40) (×109/L) |
| Monocyte | 260 (100.0%) | 0.42 (0.04–1.08) (×109/L) |
| RBC | 260 (100.0%) | 4.17 (1.58–6.57) (×1012/L) |
| Hb | 260 (100.0%) | 123.5 (22.0–156.0) (g/L) |
| Platelet | 260 (100.0%) | 248 (80–500) (×109/L) |
| Basophil | 260 (100.0%) | 0.03 (0.01–0.17) (×109/L) |
| PLR | 260 (100.0%) | 154.17 (48.48–500.00) |
| NLR | 260 (100.0%) | 2.49 (0.93–14.79) |
| MLR | 260 (100.0%) | 0.26 (0.04–1.42) |
| BLR | 260 (100.0%) | 0.021 (0.004–0.118) |
| SIRI | 260 (100.0%) | 1.02 (0.04–15.39) |
| Neoadjuvant chemotherapy | ||
| Yes | 243 (93.5%) | |
| No | 17 (6.5%) | |
| Radiotherapy | ||
| Yes | 256 (98.5%) | |
| No | 4 (1.5%) | |
| Radiotherapy dose | 256 (98.5%) | 56.35 (25.8–65.35) (gy) |
| Radiotherapy duration | 256 (98.5%) | 54 (10–96) (days) |
| Response | ||
| CR | 168 (64.6%) | |
| PR | 82 (31.5%) | |
| SD | 7 (2.7%) | |
| PD | 2 (0.8%) | |
| Not evaluated | 1 (0.4%) | |
| Recurrence | ||
| Yes | 70 (26.9%) | |
| No | 190 (73.1%) | |
| Death | ||
| Yes | 75 (28.8%) | |
| No | 178 (68.5%) | |
| Loss to follow-up | 7 (2.7%) |
PDSCC, poorly differentiated squamous cell carcinoma; MDSCC, moderately differentiated squamous cell carcinoma; WDSCC, well differentiated squamous cell carcinoma; WBC, white blood cell; RBC, red blood corpuscle; Hb, hemoglobin; PLR, platelet-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio; BLR, basophil-to-lymphocyte ratio; SIRI, systemic inflammation response index; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. aThe other four patients were not sure about the age at menopause.